Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...
Now, a new study recently published in the journal The Lancet Diabetes & Endocrinology has found that a U.S. FDA-approved ...
Three months after her breakthrough surgery at NYU Langone Health, Towana Looney, the longest-living recipient of a genetically engineered pig kidney, is headed back home to Alabama.
Lupin has received tentative approval from the Food and Drug Administration for darunavir, cobicistat, emtricitabine, and ...
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired ...
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results